Novartis India Ltd. News and Updates

Keep track of all breaking news on Novartis India Ltd. from all sources in a single place.

16 Sep 2025, 07:49PM

875.95

1.51%

Novartis' Vymada patent revoked, generics likely to cut prices by 70%

Business Standard

Novartis lost its Vymada patent in India, enabling generic drugmakers to launch versions that could slash prices by up to 70 per cent and improve access for cardiac patients

Novartis India Ltd. is trading below all available SMAs

Novartis India Ltd.

15 Sep 2025

875.95

1.51%

Novartis signs $5.7 bn licensing deal with Monte Rosa Therapeutics

Business Standard

Under the agreement, Monte Rosa will receive an upfront payment of $120 million and could earn milestone payments and royalties that lift the total value to as much as $5.7 billion

Novartis India Ltd. is trading below all available SMAs

Novartis India Ltd.

17 Jul 2025, 10:22AM

875.95

1.51%

Novartis cannot block generic version of Entresto, judge rules

Business Line

The judge also reversed her prior ruling that Novartis would likely prove that MSN's tablets looked too similar to Entresto and would confuse consumers

Novartis India Ltd. is trading below all available SMAs

Novartis India Ltd.

14 Jul 2025

875.95

1.51%

Divi's Labs Shares Slide After Novartis' Entresto Loses Patent Lawsuit

NDTV Profit

Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based drugmaker's revenue.

Novartis India Ltd. is trading below all available SMAs

Novartis India Ltd.

10 Apr 2025

875.95

1.51%

Trump's tariffs, market volatility delay marquee M&A transactions in India

Business Standard

Bankers say high-profile deals, including those involving the sale of AkzoNobel India, Novartis India, and HDB Financial Services, are now on pause as buyers seek more time to navigate valuation fog

Novartis India Ltd. is trading below all available SMAs

Novartis India Ltd.

13 Mar 2025

875.95

1.51%

Generics surge as patent expiry restores mkt pulse, boosting drug volumes

Business Standard

An analysis by Pharmarack, a market research firm, showed that 226 vildagliptin (anti-diabetic) brands are now available in the market after Novartis' patent expired in December 2019

Novartis India Ltd. is trading below all available SMAs

Novartis India Ltd.

30 Jan 2025

875.95

1.51%

Novartis India Q3 Results 2025 on 30 Jan, 2025: profit falls by 4.22% YOY, profit at 25.45 crore and revenue at 93 crore

livemint

Novartis India Q3 Results 2025 on 30 Jan, 2025: Revenue increased by 10.01% YoY & profit decreased by 4.22% YoY, profit at 25.45 crore and revenue at 93 crore

Novartis India Ltd. is trading below all available SMAs

Novartis India Ltd.

17 Jan 2025, 04:26AM

875.95

1.51%

US appeals court lifts pause on generic version of Novartis' Entresto

livemint

NOVARTIS-ENTRESTO/PATENT-LAWSUIT (PIX):US appeals court lifts pause on generic version of Novartis' Entresto

Novartis India Ltd. is trading below all available SMAs

Novartis India Ltd.

21 Nov 2024

875.95

1.51%

Novartis Raises Sales Guidance Citing Cancer, Inflammatory Drugs

NDTV Profit

The company lifted its peak sales estimates for its Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio drugs, most of which have expected US exclusivity in the 2030s or beyond.

Novartis India Ltd. is trading below all available SMAs

Novartis India Ltd.

05 Nov 2024

875.95

1.51%

Campus hiring soars as GCCs seek freshers skilled in data science and AI

Business Standard

Companies like Wells Fargo, JPMorgan Chase, Novartis, Epsilon, and EQ India are actively hiring from engineering colleges, business schools, and general degree institutions in India

Novartis India Ltd. is trading below all available SMAs

Is Novartis India Ltd. worth buying?

70 Votes:

Buy 74.29%

Sell 15.71%

Hold 10.0%